Peter Cicala - 31 Aug 2026 Form 4 Insider Report for Ernexa Therapeutics Inc. (ERNA)

Reporting relationship: Director
Issuer ticker: ERNA
Reported as of: 31 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Sep 2026, 21:56:12 UTC
Prior SEC filing: 10 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter Cicala

Key filing fact

Peter Cicala filed Form 4 for Ernexa Therapeutics Inc. (ERNA) on 01 Sep 2026.

Key facts

This page summarizes Peter Cicala's Form 4 filing for Ernexa Therapeutics Inc. (ERNA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 01 Sep 2026, 21:56.

Change

Previous filing in this sequence was filed on 10 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002011534 Primary reporting owner

Cicala Peter

Relationship: Director
Address: C/O ERNEXA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE
Signature: /s/ Peter Cicala
Signature date: 01 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares: +5,943
Change %
Price: $0.000000^*
Shares after: 5,943
Date: 31 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,943
Exercise price: $4.57
Footnotes: F1

ERNA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares: +5,083
Change %
Price: $0.000000^*
Shares after: 5,083
Date: 31 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,083
Exercise price: $4.57
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

Footnote F2

Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.